Epoetin‐associated pure red cell aplasia: past, present, and future considerations
暂无分享,去创建一个
Allen R Nissenson | Dennis W Raisch | A. Nissenson | J. Mckoy | D. Raisch | N. Casadevall | J. Rossert | R. Stonecash | Charles L Bennett | June M McKoy | Jerome Rossert | D. Cournoyer | Nicole Casadevall | Denis Cournoyer | Robin E Stonecash | C. Bennett | June M. McKoy | Robin E. Stonecash | Allen R. Nissenson | Dennis W. Raisch | J. McKoy
[1] S. Belknap,et al. Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. , 2005, Blood.
[2] J. Kaufman,et al. Subcutaneous erythropoietin therapy: efficacy and economic implications. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[3] I. Macdougall,et al. Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study , 2004, The Lancet.
[4] J. Wauters,et al. High prevalence in Switzerland of pure red-cell aplasia due to anti-erythropoietin antibodies in chronic dialysis patients: report of five cases. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[5] J. Kugler,et al. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. , 1993, Journal of the National Cancer Institute.
[6] G. Wells,et al. Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: recommendations for minimization of risk. , 2004, Journal of the American Society of Nephrology : JASN.
[7] M. Daha,et al. The detection of anti-erythropoietin antibodies in human serum and plasma. Part I. Validation of the protocol for a radioimmunoprecipitation assay. , 2003, Journal of immunological methods.
[8] J. Adamson,et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. , 1989, Annals of internal medicine.
[9] Patrick Mayeux,et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. , 2002, The New England journal of medicine.
[10] B. Alobeid,et al. Anti‐erythropoietin antibody–mediated pure red cell aplasia in a living donor liver transplant recipient treated for hepatitis C virus , 2007, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[11] Kai-Uwe Eckardt,et al. Epoetin-associated pure red cell aplasia in patients with chronic kidney disease: solving the mystery. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[12] Allen R Nissenson,et al. Pure red-cell aplasia and epoetin therapy. , 2004, The New England journal of medicine.
[13] D. Reda,et al. Potential cost savings of erythropoietin administration in end-stage renal disease. , 2002, The American journal of medicine.
[14] P. Schatz,et al. Hematide is immunologically distinct from erythropoietin and corrects anemia induced by antierythropoietin antibodies in a rat pure red cell aplasia model. , 2007, Experimental hematology.
[15] I. Macdougall,et al. Re-challenging patients who developed pure red cell aplasia with epoetin: can it be done? , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[16] R. Peces,et al. Antibodies against recombinant human erythropoietin in a patient with erythropoietin-resistant anemia. , 1996, The New England journal of medicine.
[17] N. Casadevall,et al. Pure red-cell aplasia due to anti-erythropoietin antibodies. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[18] A. Santoro,et al. Successful resumption of epoetin alfa after rituximab treatment in a patient with pure red cell aplasia. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[19] Steven J. Swanson,et al. Evaluation of Methods to Detect and Characterize Antibodies against Recombinant Human Erythropoietin , 2004, Nephron Clinical Practice.
[20] S S Prabhakar,et al. Antibodies to recombinant human erythropoietin causing pure red cell aplasia. , 1997, Clinical nephrology.
[21] M. Parnham,et al. Non-clinical safety studies on biosimilar recombinant human erythropoietin. , 2007, Basic & clinical pharmacology & toxicology.
[22] A. Sanyal,et al. Antibody-Mediated Pure Red Cell Aplasia Due to Epoetin Alfa During Antiviral Therapy of Chronic Hepatitis C , 2005, The American Journal of Gastroenterology.
[23] L. Sokol,et al. Pure red-cell aplasia and recombinant erythropoietin. , 2002, The New England journal of medicine.
[24] A. Levin,et al. Successful reintroduction of a different erythropoiesis-stimulating agent after pure red cell aplasia: relapse after successful therapy with prednisone. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[25] A. Mooney,et al. Four cases of pure red cell aplasia secondary to epoetin beta, with strong temporal relationships. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[26] I. Macdougall. Novel erythropoiesis-stimulating agents: a new era in anemia management. , 2008, Clinical journal of the American Society of Nephrology : CJASN.
[27] N. Casadevall,et al. Autoantibodies against erythropoietin in a patient with pure red-cell aplasia. , 1996, The New England journal of medicine.
[28] N. Casadevall. Antibodies against rHuEPO: native and recombinant. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[29] N. Casadevall,et al. The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. , 2005, Kidney international.
[30] C. Bauer,et al. Erythropoietin: Molecular Physiology and Clinical Applications , 1993 .